ARTICLE SUMMARY:
In four years and on less than $10 million, Stimwave has introduced a novel device for the treatment of pain and the clinicians are calling it “disruptive.”
Medical devices often take a back seat to drugs as a first-line treatment for various diseases and disorders, even though drug therapy can have significant downsides, including compliance issues, cost, and systemic side effects.
